Roninson I B
Department of Genetics, University of Illinois, Chicago 60612.
Mutat Res. 1992 May;276(3):151-61. doi: 10.1016/0165-1110(92)90005-t.
This review describes the features of gene amplification associated with the selection of multidrug-resistant cell lines. Some of these lines carry multiple copies of the MDR1 gene that encodes P-glycoprotein, a broad specificity efflux pump. The MDR1 gene was initially identified as the common component of the amplicons found in multidrug-resistant cell lines selected with different drugs. Subsequent studies have established that increased MDR1 expression is sufficient for the multidrug-resistant phenotype. MDR1-containing amplicons may include a number of additional transcribed genes that do not appear to contribute to multidrug resistance. MDR1 amplification is associated with specific chromosomal changes and apparently non-random recombinational events. Increased expression of the MDR1 gene, however, does not necessarily require gene amplification. Although amplification of the MDR1 gene has not been found in clinical tumor samples, increased expression of this gene is commonly observed in different types of cancer and appears to be a significant marker of clinical drug resistance.
本综述描述了与多药耐药细胞系选择相关的基因扩增特征。其中一些细胞系携带编码P-糖蛋白(一种广谱特异性外排泵)的MDR1基因的多个拷贝。MDR1基因最初被鉴定为在用不同药物选择的多药耐药细胞系中发现的扩增子的共同组成部分。随后的研究证实,MDR1表达增加足以导致多药耐药表型。含有MDR1的扩增子可能包括一些似乎对多药耐药没有贡献的额外转录基因。MDR1扩增与特定的染色体变化以及明显的非随机重组事件有关。然而,MDR1基因表达增加不一定需要基因扩增。虽然在临床肿瘤样本中未发现MDR1基因扩增,但在不同类型的癌症中普遍观察到该基因表达增加,并且似乎是临床耐药性的一个重要标志物。